On February 17, 2026, Danaher Corporation announced an agreement to acquire Masimo Corporation in an all-cash transaction valued at approximately $9.9Bn, or $180.00 per share. The transaction may reflect a broader consolidation trend taking shape across the acute care diagnostics sector — one in which large, diversified life science platforms are increasingly seeking to bring patient monitoring and telehealth-adjacent technology in-house rather than address these capabilities through partnerships alone.

The transaction is anticipated to close in the second half of 2026, subject to customary regulatory approvals.

Strategic Reasoning

Danaher is a Washington, D.C.-based science and technology conglomerate with operations spanning life sciences and diagnostics, designing and manufacturing instruments, software and consumables used across research, healthcare and industrial applications. Danaher generated approximately $24.6Bn in total revenue in 2025. Central to its acquisition strategy is the Danaher Business System (DBS) — a lean management framework derived from the Toyota Production System that Danaher applies across every business it acquires to drive operational efficiency and performance improvement.

Masimo is a leading developer of patient monitoring technology used widely in hospital and acute care settings, best known for its Signal Extraction Technology (SET) pulse oximetry system, which measures blood oxygen saturation and heart rate.

For Danaher, the acquisition of Masimo is expected to expand a diagnostics segment that generated approximately $10.0Bn in revenue in 2025 out of total annual revenues of roughly $24.6Bn. Masimo is anticipated to operate as a standalone business unit and brand within Danaher’s diagnostics division, maintaining its existing identity and product architecture while gaining access to Danaher’s global commercial infrastructure and its proprietary operating framework, the Danaher Business System. This structure may allow Masimo to preserve the operational independence that has historically underpinned its product development capabilities, while potentially benefiting from Danaher’s scale across international markets.

The transaction may also accelerate Danaher’s broader ambitions in the telehealth space. Masimo’s monitoring technology has applications not only in traditional inpatient acute care settings but in remote and ambulatory care environments — a market that has seen sustained investment and growth in recent years. Masimo’s healthcare revenue (which is understood to include a veterinary segment alongside its core hospital business) is estimated to have grown at approximately 9% in the period leading up to the announcement, suggesting continued underlying demand for its core products. The global market for pulse oximetry systems is projected to reach an estimated $2.1Bn by 2034, a trajectory that may reinforce the long-term strategic rationale for the deal.

Market Context

Masimo enters this transaction following a period of significant operational and governance disruption. The company faced sustained shareholder pressure stemming from its $1Bn acquisition of consumer audio brand Sound United in 2022 — a move widely viewed as a departure from Masimo’s core healthcare mission that drew a high-profile activist campaign led by New York-based Politan Capital. The fallout from that campaign ultimately contributed to the departure of Masimo’s founder and longtime CEO, Joe Kiani, a development that may have prompted the company to sharpen its focus on its core medical device business in the period that followed.

More recently, Masimo prevailed in a patent infringement dispute against Apple related to blood oxygen monitoring technology incorporated into consumer wearables, with a California court awarding Massimo $634MM in damages in

November 2025. That outcome may have meaningfully clarified the value and defensibility of Masimo’s core intellectual property portfolio in the months preceding this transaction and may have contributed to the strategic confidence with which Danaher ultimately approached the acquisition. The resolution of any remaining related proceedings — including matters that may involve the U.S. Customs and Border Protection agency — could continue to bear on Masimo’s business in the near term.

Offer Price and Market response

The offer price of $180.00 per share represents a premium of approximately 38% to Masimo’s pre-announcement trading price of approximately $130.15. Masimo’s shares rose over 34% on the day of the announcement, reaching approximately $175.00 per share at market open on February 17, 2026.

Industry Implications

Should the transaction close as anticipated, it may signal increased appetite among diversified life science and diagnostics platforms for acquisitions in the acute care monitoring space — particularly as healthcare systems continue to face pressure to improve patient outcomes while managing cost. Masimo’s position at the intersection of hospital infrastructure, proprietary signal processing and an emerging remote monitoring market could make the combined business a more competitive participant in what may be a rapidly evolving care delivery landscape.

The deal could also reflect a broader pattern of consolidation in which large platform acquirers seek to bring differentiated, IP-backed medical technology in-house ahead of what may be an accelerating shift toward data-driven and continuous patient monitoring across both acute and ambulatory settings. The extent to which Danaher is able to leverage Masimo’s brand and technology into adjacent segments will likely depend on integration timelines and the pace of commercial execution following close — factors that may take several years to assess with confidence.

About DelMorgan & Co. (www.delmorganco.com)

With over $300 billion of successful transactions in over 80 countries, DelMorgan‘s Investment Banking professionals have worked on some of the most challenging, most rewarding and highest profile transactions in the U.S. and around the globe. DelMorgan specializes in capital raising and M&A advisor services for companies across all industries and is recognized as one of the leading investment banking practices in California and globally.